Table 2

Pooling of the prevalence of newly identified thoracic abdominal aneurysm or thoracic abdominal dilatation, using data from imaging studies

StudyTAA/TAD prevalence (95% CI) by binomial exact method, %TAA/TAD prevalence in meta analysis (95% CI), %Model 1 (4 full reports and 1 meeting abstract) weighting, %Model 2 (4 full reports only) weighting, %Model 3 (biopsy-proven GCA only), %
Prieto-Gonzalez et al415.0 (5.7 to 29.8)15.0 (3.9 to 26.1)15.2220.4539.49
Agard et al318.2 (5.2 to 40.3)18.2 (2.1 to 34.3)7.529.6418.61
Garcia-Martinez et al2320.4 (10.6 to 33.5)20.4 (9.6 to 31.1)16.0721.7141.90
Karamagkiolis et al298.2 (2.3 to 19.6)8.2 (0.5 to 15.8)29.04
Both et al3017.1 (10.5 to 25.7)17.1 (9.9 to 24.4)32.1548.20
Estimated pooled prevalence (95% CI), %14.8 (10.3 to 19.3)17.5 (12.5 to 22.5)17.8 (10.9 to 24.8)
Number of patients needed to be imaged in order to pick up one new thoracic aortic aneurysm or dilatation, calculated from pooled prevalence (95% CI)6.8 (5.2 to 9.7)5.7 (4.4 to 8.0)5.6 (4.0 to 9.2)
  • Model 1: goodness-of-fit χ2 value heterogeneity was 4.49, p>χ2=0.34. I2 (variation in prevalence attributable to heterogeneity)=10.8%.

  • Model 2: goodness-of-fit χ2 value heterogeneity was 0.49, p>χ2=0.92. I2 (variation in prevalence attributable to heterogeneity)=0.0%.

  • Model 3: goodness-of-fit χ2 value heterogeneity was 0.47, p>χ2=0.791. I2 (variation in prevalence attributable to heterogeneity)=0.0%.

  • GCA, giant cell arteritis; TAA, thoracic aortic aneurysm; TAD, thoracic aortic dilatation.